Migration of dendritic cell based cancer vaccines: in vivo veritas?
Open accessAbstract
Ex vivo generated cancer vaccines based on dendritic cells (DCs) are currently applied in the clinic. The migration of DCs from the tissues to the lymph nodes is tightly controlled and involves many different mediators and their receptors. A recent study demonstrated that the rate of migration of antigen-bearing DCs in situ from the skin to the lymph node is 100-fold higher than previously estimated. The migration of ex vivo generated DCs is rather inefficient but can be improved by pre-conditioning of the vaccine injection site with inflammatory cytokines. An alternative approach that is currently being explored is to target tumor antigens directly to DCs in situ, thereby exploiting the intricate migratory capacity of DCs in vivo. Recent advances have been made in understanding DC migration in the context of DC-based vaccines.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Similar time kinetics have been reported for intradermally injected DCs in melanoma patients.
“Similar time kinetics have been reported for intradermally injected DCs in melanoma patients.52,53”
From Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells (2006) · cites this paper as [53]
The ‘Migration of ex vivo generated DC vaccines’ section reports that intradermally administered DCs reach draining lymph nodes, and the reference annotation for de Vries et al. identifies melanoma patients. Neither passage gives the time course of that migration, so the claimed similarity in time kinetics is unsupported by this copy. (LLM, conf=0.84)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
No references could be resolved yet.
Research works printed but not linked: 23
- Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G: Dendritic cells as vectors for therapy. Cell 2001, 106:271-274.
- Steinman RM, Pope M: Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 2002, 109:1519-1526.
- Bousso P, Robey E: Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes. Nat Immunol 2003, 4:579-585.
- Miller MJ, Hejazi AS, Wei SH, Cahalan MD, Parker I: T cell repertoire scanning is promoted by dynamic dendritic cell behavior and random T cell motility in the lymph node. Proc Natl Acad Sci USA 2004, 101:998-1003.
- MartIn-Fontecha A, Sebastiani S, Hopken UE, Uguccioni M, Lipp M, Lanzavecchia A, Sallusto F: Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med 2003, 198:615-621.
- Nair S, McLaughlin C, Weizer A, Su Z, Boczkowski D, Dannull J, Vieweg J, Gilboa E: Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol 2003, 171:6275-6282.
- Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 1998, 4:328-332.
- Jonuleit H, Giesecke-Tuettenberg A, Tuting T, Thurner-Schuler B, Stuge TB, Paragnik L, Kandemir A, Lee PP, Schuler G, Knop J et al.: A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 2001, 93:243-251.
- Mackensen A, Krause T, Blum U, Uhrmeister P, Mertelsmann R, Lindemann A: Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells. Cancer Immunol Immunother 1999, 48:118-122.
- Mullins DW, Sheasley SL, Ream RM, Bullock TN, Fu YX, Engelhard VH: Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med 2003, 198:1023-1034.
- Mora JR, von Andrian UH: Retinoic acid; an educational ''vitamin elixir'' for gut-seeking T cells. Immunity 2004, 21:458-460.
- Engering A, Geijtenbeek TB, van Kooyk Y: Immune escape through C-type lectins on dendritic cells. Trends Immunol 2002, 23:480-485.
- Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM: Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 2002, 196:1627-1638.
- Schjetne KW, Thompson KM, Aarvak T, Fleckenstein B, Sollid LM, Bogen B: A mouse C(kappa)-specific T cell clone indicates that DC-SIGN is an efficient target for antibody-mediated delivery of T cell epitopes for MHC class II presentation. Int Immunol 2002, 14:1423-1430.
- Mahnke K, Qian Y, Knop J, Enk AH: Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells. Blood 2003, 101:4862-4869.
- Toes RE, Ossendorp F, Offringa R, Melief CJ: CD4 T cells and their role in antitumor immune responses. J Exp Med 1999, 189:753-756.
- Tillman BW, de Gruijl TD, Luykx-de Bakker SA, Scheper RJ, Pinedo HM, Curiel TJ, Gerritsen WR, Curiel DT: Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. J Immunol 1999, 162:6378-6383.
- de Gruijl TD, Luykx-de Bakker SA, Tillman BW, van den Eertwegh AJ, Buter J, Lougheed SM, van der Bij GJ, Safer AM, Haisma HJ, Curiel DT et al.: Prolonged maturation and enhanced transduction of dendritic cells migrated from human skin explants after in situ delivery of CD40-targeted adenoviral vectors. J Immunol 2002, 169:5322-5331.
- Ross R, Sudowe S, Beisner J, Ross XL, Ludwig-Portugall I, Steitz J, Tuting T, Knop J, Reske-Kunz AB: Transcriptional targeting of dendritic cells for gene therapy using the promoter of the cytoskeletal protein fascin. Gene Ther 2003, 10:1035-1040.
- Furumoto K, Soares L, Engleman EG, Merad M: Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J Clin Invest 2004, 113:774-783.
- Kirk CJ, Hartigan-O'Connor D, Mule JJ: The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res 2001, 61:8794-8802.
- Guo J, Wang B, Zhang M, Chen T, Yu Y, Regulier E, Homann HE, Qin Z, Ju DW, Cao X: Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity. Gene Ther 2002, 9:793-803.
- Bonnotte B, Crittenden M, Larmonier N, Gough M, Vile RG: MIP-3alpha transfection into a rodent tumor cell line increases intratumoral dendritic cell infiltration but enhances (facilitates) tumor growth and decreases immunogenicity. J Immunol 2004, 173:4929-4935.
Cited by
Sorted by citations
de Vries, I. J. M., Lesterhuis, W. J., Barentsz, J. O., Verdijk, P., van Krieken, J. H., Boerman, O. C., Oyen, W. J. G., Bonenkamp, J. J., Boezeman, J. B., Adema, G. J., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1154 · Cited by 821 · see citing works
Self-citationHoltkamp, S., Kreiter, S., Selmi, A., Simon, P., Koslowski, M., Huber, C., Türeci, O., & Sahin, U. (2006) · Blood · doi:10.1182/blood-2006-04-015024 · Cited by 625 · see citing works
Type I interferons and dendritic cells in cancer immunotherapy
(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.06.001 · Cited by 124 · see citing works
Immunotherapeutic advances in glioma management: The rise of vaccine‐based approaches
Andrew Awuah, W., Shah, M. H., Tan, J. K., Ranganathan, S., Sanker, V., Darko, K., Tenkorang, P. O., Adageba, B. B., Ahluwalia, A., Shet, V., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70013 · Cited by 14 · see citing works
- Authors
- Adema, G. J., de Vries, I. J. M., Punt, C. J., & Figdor, C. G.
- Corresponding author
- Adema, Gosse J
- Venue
- Current Opinion in Immunology
- Publisher
- Elsevier BV
- Published
- 2005-04
- Volume
- 17
- Issue
- 2
- Pages
- 170-174
- ISSN
- 0952-7915 (ISSN-L)
- OpenAlex
- W2002918113
- Cited by
- 134
- References
- 0
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 6 · 2022: 2 · 2020: 1 · 2019: 6 · 2018: 1 · 2017: 5 · 2016: 5 · 2015: 2 · 2014: 7 · 2013: 5 · 2012: 8
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Current Opinion in Immunology (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- KWF Kankerbestrijding
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- dendritic cell migration, dendritic cell-based cancer vaccine, ex vivo dendritic cell generation, lymph node homing, inflammatory cytokines, tumor antigen targeting
- MeSH terms
- Animals, Antigens, Neoplasm, Cell Movement, Dendritic Cells, Humans, Injections, Intralymphatic, Neoplasms, Antigen Presentation, Cancer Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
